Dr. Biana Godin earned her Ph.D. in Pharmaceutical Sciences from the Hebrew University of Jerusalem in 2006. During her Ph.D. studies, Dr. Godin focused on designing a non-invasive treatment for the hard-to-treat skin deep infections and on nasal delivery of proteins. She was recruited as a Postdoctoral trainee in the field of Cancer Nanotechnology to the University of Texas Health Sciences Center. Her postdoctoral research focused on injectable multistage nanovectors (MSVs) for cancer treatment and imaging. Her work provided insightful understanding of the interactions of MSVs with immune cells in vivo and in vitro, biocompatibility of MSV, effect of geometry and targeting moieties on MSV biodistribution, and evaluation of MSV systems as near-infra red and MRI imaging agents. In October 2010, Dr. Godin joined the Department of Nanomedicine at the Research Institute. 

Research in Dr. Godin's lab, largely funded by federal and foundation grants, focuses on developing physiologically relevant in vitro and in vivo disease models and exploiting physical and biological mechanisms to improve currently available therapeutic options in oncology and obstetrics. Dr. Godin considers herself a translational scientist on the interception of biological and physical sciences, with the ultimate goal of bringing advanced and safe therapies and the techniques to personalize therapies into the clinic to benefit patients.

Dr. Godin has more than 200 scientific publications, received multiple federal and foundation-based grants and participated in multiple national and international grant review panels. 

Dr. Godin and her group published numerous peer-reviewed articles, book chapters and reviews in top journals including Nature Nanotechnology, Advanced Functional Materials, Journal of Controlled Release and Cancer Research. She also received national and international awards and other recognitions for her work and is on the editorial board and review board for numerous journals. 

Dr. Godin's research focuses primarily on the following areas:

-Employing principles of nanomedicine in Ob/Gyn

-Targeting liver metastasis with advanced nanocarriers

-Novel strategies to target tumor microenvironment

-Advanced patient-derived ex vivo disease models for personalized therapies

The main objective of these studies is to provide innovative approaches to treatment and diagnosis of cancer and Ob/Gyn disorders.